Literature DB >> 21283990

Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research.

Dario Baratti1, Shigeki Kusamura, Marcello Deraco.   

Abstract

Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and locally aggressive tumor with poor prognosis. Currently, no standard therapy is available. The biology of this disease is still poorly understood. We performed a systematic search of relevant studies on clinical management and biological research of DMPM. Trials were selected using a predetermined protocol. The current evidence suggests that cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) results in improved survival. Biological understanding of DMPM is currently evolving.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21283990     DOI： 10.1002/jso.21787

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  14 in total

1.  Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.

Authors:  Anuradha Chandramohan; Andrew Thrower; Nehal Shah; Faheez Mohamed
Journal:  Br J Radiol       Date:  2017-08-22       Impact factor: 3.039

Review 2.  Meningeal metastasis of a malignant peritoneal mesothelioma: A case report and literature review.

Authors:  Yaofei Jiang; Zijie Mei; Hong Cao; Sirui Li; Haibo Xu; Hui Qiu; Yu Liu
Journal:  Cancer Biol Ther       Date:  2019-08-14       Impact factor: 4.742

3.  Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Authors:  Alain C Borczuk; Jianming Pei; Robert N Taub; Brynn Levy; Odelia Nahum; Jinli Chen; Katherine Chen; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2016-02-06       Impact factor: 4.742

4.  Hemodynamic Monitoring During Heated Intraoperative Intraperitoneal Chemotherapy Using the FloTrac/Vigileo System.

Authors:  Christos Mavroudis; Leonidas Alevizos; Konstantinos M Stamou; Theodosia Vogiatzaki; Savvas Eleftheriadis; Odysseas Korakianitis; Antonios A Tentes; Christos Iatrou
Journal:  Int Surg       Date:  2015-01-15

Review 5.  Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes.

Authors:  Harveshp Mogal; Konstantinos Chouliaras; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 6.  Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives.

Authors:  J Spiliotis; E Halkia; E de Bree
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

Review 7.  Advances in the management of peritoneal mesothelioma.

Authors:  Ali Raza; Wei-Ching Huang; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

8.  Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Authors:  Tomoko Akahane; Akira Hirasawa; Issei Imoto; Aki Okubo; Manabu Itoh; Yoshiko Nanki; Tomoko Yoshihama; Eichiro Tominaga; Daisuke Aoki
Journal:  Hum Cell       Date:  2019-10-03       Impact factor: 4.174

9.  Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer.

Authors:  Sarah L Suchy; Rodney J Landreneau; Matthew J Schuchert; Dakun Wang; Paul R Ervin; Stacey L Brower
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

10.  CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis.

Authors:  Wen-jie Yin; Guo-qi Zheng; Yue-feng Chen; De-qiang Chen; Ning-ning Sun; Yu-xin Yang; Xin-yi Sun; Li-qing Kang
Journal:  Radiol Med       Date:  2015-12-11       Impact factor: 3.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.